BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 16426593)

  • 21. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension.
    Derosa G; D'Angelo A; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo S; Montagna L; Gravina A; Ferrari I; Galli S; Paniga S; Tinelli C; Cicero AF
    Endothelium; 2006; 13(3):227-31. PubMed ID: 16840178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Matrix metalloproteinase-1 and its inhibitor, TIMP-1, in systolic heart failure: relation to functional data and prognosis.
    Jordán A; Roldán V; García M; Monmeneu J; de Burgos FG; Lip GY; Marín F
    J Intern Med; 2007 Sep; 262(3):385-92. PubMed ID: 17697160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
    Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
    Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats.
    Sun SZ; Wang Y; Li Q; Tian YJ; Liu MH; Yu YH
    Chin Med J (Engl); 2006 May; 119(10):814-21. PubMed ID: 16732983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
    Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating matrix metalloproteinases and their endogenous inhibitors in patients with erectile dysfunction.
    Muniz JJ; Lacchini R; Belo VA; Nobre YT; Tucci S; Martins AC; Tanus-Santos JE
    Int J Impot Res; 2012; 24(1):38-43. PubMed ID: 21918531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: relationship to disease severity.
    Tayebjee MH; Tan KT; MacFadyen RJ; Lip GY
    J Intern Med; 2005 Jan; 257(1):110-6. PubMed ID: 15606382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating matrix metalloproteinase-8 (MMP-8) and MMP-9 are increased in chronic periodontal disease and decrease after non-surgical periodontal therapy.
    Marcaccini AM; Novaes AB; Meschiari CA; Souza SL; Palioto DB; Sorgi CA; Faccioli LH; Tanus-Santos JE; Gerlach RF
    Clin Chim Acta; 2009 Nov; 409(1-2):117-22. PubMed ID: 19751716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TNF-alpha is an independent serum marker for proliferative retinopathy in type 1 diabetic patients.
    Gustavsson C; Agardh E; Bengtsson B; Agardh CD
    J Diabetes Complications; 2008; 22(5):309-16. PubMed ID: 18413212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Assay of matrix metalloproteinase levels and their endogenous inhibitors in patients with laryngeal carcinoma].
    Klisho EV; Savenkova OV; Kondakova IV; Perel'muter VM; Choĭnzonov EL; Shishkin DA
    Vopr Onkol; 2007; 53(1):26-31. PubMed ID: 17649730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum levels of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases 1 in subacute sclerosing panencephalitis.
    Ichiyama T; Siba P; Suarkia D; Takasu T; Miki K; Kira R; Kusuhara K; Hara T; Toyama J; Furukawa S
    J Neurol Sci; 2007 Jan; 252(1):45-8. PubMed ID: 17118404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Different circulating metalloproteinases profiles in women with migraine with and without aura.
    Martins-Oliveira A; Speciali JG; Dach F; Marcaccini AM; Gonçalves FM; Gerlach RF; Tanus-Santos JE
    Clin Chim Acta; 2009 Oct; 408(1-2):60-4. PubMed ID: 19627981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Matrix metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes mellitus.
    Derosa G; Avanzini MA; Geroldi D; Fogari R; Lorini R; De Silvestri A; Tinelli C; Rondini G; d'Annunzio G
    Diabetes Res Clin Pract; 2005 Nov; 70(2):119-25. PubMed ID: 16188574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Matrix metalloproteinases (MMP-8, MMP-9) and the tissue inhibitors of metalloproteinases (TIMP-1, TIMP-2) in patients with fungal keratitis.
    Rohini G; Murugeswari P; Prajna NV; Lalitha P; Muthukkaruppan V
    Cornea; 2007 Feb; 26(2):207-11. PubMed ID: 17251814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum MMP-1 and TIMP-1 levels are increased in patients with psoriatic arthritis and their siblings.
    Myers A; Lakey R; Cawston TE; Kay LJ; Walker DJ
    Rheumatology (Oxford); 2004 Mar; 43(3):272-6. PubMed ID: 14523226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents.
    Belo VA; Souza-Costa DC; Lana CM; Caputo FL; Marcaccini AM; Gerlach RF; Bastos MG; Tanus-Santos JE
    Clin Biochem; 2009 Jul; 42(10-11):984-90. PubMed ID: 19358835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tissue inhibitors of matrix metalloproteinase-1 levels are increased in serum of patients with allergic contact dermatitis.
    Reduta T; Laudańska H; Laudanski P
    Contact Dermatitis; 2007 Aug; 57(2):100-4. PubMed ID: 17627649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function.
    Kosmala W; Plaksej R; Przewlocka-Kosmala M; Kuliczkowska-Plaksej J; Bednarek-Tupikowska G; Mazurek W
    Int J Obes (Lond); 2008 May; 32(5):763-71. PubMed ID: 18197181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monocyte matrix and ADAM metalloproteinase expression in type 2 diabetes after aspirin therapy.
    Sampson M; Wall S; Baugh M; Worley J; Davies I; Hughes D; Gavrilovic J
    Diabetes Res Clin Pract; 2006 Jan; 71(1):45-51. PubMed ID: 16023759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum levels of matrix metalloproteinase-9, tissue inhibitors of metalloproteinase-1 and their ratio are associated with impaired lung function in the elderly: a population-based study.
    Olafsdóttir IS; Janson C; Lind L; Hulthe J; Gunnbjörnsdóttir M; Sundström J
    Respirology; 2010 Apr; 15(3):530-5. PubMed ID: 20337997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.